Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-09

Alkermes plc. (ALKS)

CEO Richard Pops was paid $7,915,081 in fiscal year 2025, ↓ down 21.9% from fiscal year 2024, the 12th percentile of its disclosed peer group (SEC filing 0001193125-26-143977 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$7,915,081 ↓
Richard Pops total, FY2025
12th
CEO pay percentile vs peers
30:1
CEO-to-median pay ratio
98.73%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Richard Pops (Chief Executive Officer and Chairman of the Board), FY2025 total compensation $7,915,081 (base salary $1,250,769) [exec_comp, SEC accession 0001193125-26-143977, filed 2026-04-06]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

ALKS's next annual pay disclosure, estimated April 5, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Richard Pops$1,250,769$0$0$5,020,812$1,626,000$0$17,500$7,915,081
Chief Executive Officer and Chairman of the Board
Blair Jackson736,45001,333,3561,324,981618,618017,5004,030,905
Executive Vice President, Chief Operating Officer and Chief Risk Officer; Former Interim Principal Financial Officer
Joshua Reed181,97801,155,0312,334,091118,28607,6883,797,074
Senior Vice President, Chief Financial Officer
Craig Hopkinson764,83701,100,0011,093,107642,463017,5003,617,908
Executive Vice President, Research and Development and Chief Medical Officer
David Gaffin684,49701,100,0011,093,107574,978017,5003,470,083
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
C. Todd Nichols614,8690866,683861,234430,408017,5002,790,694
Senior Vice President, Chief Commercial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Richard Pops$7,915,081$10,131,193$9,442,066↓ −2,216,112
Blair Jackson4,030,9054,891,0344,561,915↓ −860,129
Joshua Reed3,797,074———
Craig Hopkinson3,617,9084,343,9914,226,388↓ −726,083
David Gaffin3,470,0834,115,3554,135,728↓ −645,272
C. Todd Nichols2,790,6943,319,071—↓ −528,377

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Alkermes plc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ALKS reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Alkermes plc. Peer Teardown Report

$7,915,081 Richard Pops total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 9, 2026 · Source: 0001193125-26-143977 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for ALKS

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
ALKSon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order ALKS

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against ALKS
25 companies name ALKS as a compensation peer

Each company listed discloses ALKS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ALKS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the Alkermes plc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Brian P. McKeonIndependent Director$491,333
Cato T. Laurencin, M.D., Ph.DIndependent Director$461,014
Christopher I. Wright, M.D., Ph.DIndependent Director$477,843
David A. Daglio, JrFormer director (through FY2025)—
Emily Peterson AlvaFormer director (through FY2025)$515,258
Frank Anders WilsonLead Independent Director$527,234
Nancy L. Snyderman, M.DIndependent Director$479,135
Nancy S. LurkerIndependent Director$476,212
Richard B. Gaynor, M.DIndependent Director$474,014
Shane M. CookeIndependent Director$484,751
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
David GaffinEVP, CLO, Alkermes, Inc.2026-04-06D2,034$35$70,315CommonForm 4 ↗
Nancy S. LurkerDirector2026-04-11D3,751——Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-04-11D9013330,057CommonForm 4 ↗
Nancy S. LurkerDirector2026-04-11A3,751——CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-05-01D5,00000Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-05-01D9,00033300,560CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-05-01A5,0001996,700CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-05-04D2,0343367,529CommonForm 4 ↗
Richard GaynorDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Brian P. McKeonDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Brian P. McKeonDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Christopher I. WrightDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Christopher I. WrightDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-21A6,142——CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-21A6,142——CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-21A6,142——CommonForm 4 ↗
Shane M. CookeDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-21A6,142——CommonForm 4 ↗
Richard GaynorDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-21A6,142——CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Brian P. McKeonDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Brian P. McKeonDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Brian P. McKeonDirector2026-05-21A6,142——CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-21A6,142——CommonForm 4 ↗
Christopher I. WrightDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Christopher I. WrightDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Christopher I. WrightDirector2026-05-21A6,142——CommonForm 4 ↗
Shane M. CookeDirector2026-05-21D3,20737118,499CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29D12,82500Derivative, Class A CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29A3,3922067,942CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29D3,39200Derivative, Class A CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29D16,21742687,007CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29A12,82519248,036CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-06-01D5,00000Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-06-01D9,00042375,044CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-06-01A5,0001996,700CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-06-04D2,0344387,564CommonForm 4 ↗
Christopher I. WrightDirector2026-06-12D2,0004590,200CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-07-01D5,00000Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-07-01A5,0001996,700CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-07-01D8,30051427,129CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-07-01D7005236,492CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-07-06D2,03454109,897CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03D16,52400Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03A16,52447772,001CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-08-03A4,89625120,393CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-08-03D2,0344998,812CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-08-03D4,89600Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-08-03—104——1 insider, 1 accrual row
Craig HopkinsonEVP R&D, Chief Medical Officer2026-08-03D9,00049437,220CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03D44,472502,239,076CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-08-03A104192,011CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03D27,94800Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03A27,948471,305,731CommonForm 4 ↗
Blair JacksonDirector2026-08-05A124,30500Derivative, Class A CommonForm 4 ↗
Blair JacksonDirector2026-08-05A93,22900Derivative, Class A CommonForm 4 ↗
C. Todd NicholsSVP, Chief Commercial Officer2026-08-17D6,91249339,967CommonForm 4 ↗
C. Todd NicholsSVP, Chief Commercial Officer2026-08-17D6645032,969CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-09-01A5,00025122,950CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-09-01D5,00000Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-09-01D9,00047422,874CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-09-03D2,0344897,652CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-10-02D2,0344183,455CommonForm 4 ↗
Anne Clem WhitakerDirector2026-10-07A17,99800Derivative, Class A CommonForm 4 ↗
Anne Clem WhitakerDirector2026-10-07A7,23900Derivative, Class A CommonForm 4 ↗
Joshua ReedSVP, Chief Financial Officer2026-10-08D9,164——Derivative, Class A CommonForm 4 ↗
Joshua ReedSVP, Chief Financial Officer2026-10-08D4,06940163,208CommonForm 4 ↗
Joshua ReedSVP, Chief Financial Officer2026-10-08A9,164——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 92 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
David GaffinEVP, CLO, Alkermes, Inc.2026-04-06D2,034$35$70,315CommonForm 4 ↗
Nancy S. LurkerDirector2026-04-11D3,751——Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-04-11D9013330,057CommonForm 4 ↗
Nancy S. LurkerDirector2026-04-11A3,751——CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-05-01D5,00000Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-05-01D9,00033300,560CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-05-01A5,0001996,700CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-05-04D2,0343367,529CommonForm 4 ↗
Richard GaynorDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Brian P. McKeonDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Brian P. McKeonDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Christopher I. WrightDirector2026-05-20A5,40900Derivative, Class A CommonForm 4 ↗
Christopher I. WrightDirector2026-05-20A11,53800Derivative, Class A CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-21A6,142——CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-21A6,142——CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Richard GaynorDirector2026-05-21A6,142——CommonForm 4 ↗
Shane M. CookeDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Shane M. CookeDirector2026-05-21A6,142——CommonForm 4 ↗
Richard GaynorDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Cato T. LaurencinDirector2026-05-21A6,142——CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Nancy S. LurkerDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Brian P. McKeonDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Brian P. McKeonDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Brian P. McKeonDirector2026-05-21A6,142——CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-21A6,142——CommonForm 4 ↗
Christopher I. WrightDirector2026-05-21D6,142——Derivative, Class A CommonForm 4 ↗
Christopher I. WrightDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Christopher I. WrightDirector2026-05-21A6,142——CommonForm 4 ↗
Shane M. CookeDirector2026-05-21D3,20737118,499CommonForm 4 ↗
Frank Anders WilsonDirector2026-05-21D1,4753754,501CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29D12,82500Derivative, Class A CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29A3,3922067,942CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29D3,39200Derivative, Class A CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29D16,21742687,007CommonForm 4 ↗
Samuel Joseph ParisiVP, Finance (Interim PAO)2026-05-29A12,82519248,036CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-06-01D5,00000Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-06-01D9,00042375,044CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-06-01A5,0001996,700CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-06-04D2,0344387,564CommonForm 4 ↗
Christopher I. WrightDirector2026-06-12D2,0004590,200CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-07-01D5,00000Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-07-01A5,0001996,700CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-07-01D8,30051427,129CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-07-01D7005236,492CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-07-06D2,03454109,897CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03D16,52400Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03A16,52447772,001CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-08-03A4,89625120,393CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-08-03D2,0344998,812CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-08-03D4,89600Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-08-03D10400Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-08-03D9,00049437,220CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03D44,472502,239,076CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-08-03A104192,011CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03D27,94800Derivative, Class A CommonForm 4 ↗
nancy lynn snyderman MDDirector2026-08-03A27,948471,305,731CommonForm 4 ↗
Blair JacksonDirector2026-08-05A124,30500Derivative, Class A CommonForm 4 ↗
Blair JacksonDirector2026-08-05A93,22900Derivative, Class A CommonForm 4 ↗
C. Todd NicholsSVP, Chief Commercial Officer2026-08-17D6,91249339,967CommonForm 4 ↗
C. Todd NicholsSVP, Chief Commercial Officer2026-08-17D6645032,969CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-09-01A5,00025122,950CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-09-01D5,00000Derivative, Class A CommonForm 4 ↗
Craig HopkinsonEVP R&D, Chief Medical Officer2026-09-01D9,00047422,874CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-09-03D2,0344897,652CommonForm 4 ↗
David GaffinEVP, CLO, Alkermes, Inc.2026-10-02D2,0344183,455CommonForm 4 ↗
Anne Clem WhitakerDirector2026-10-07A17,99800Derivative, Class A CommonForm 4 ↗
Anne Clem WhitakerDirector2026-10-07A7,23900Derivative, Class A CommonForm 4 ↗
Joshua ReedSVP, Chief Financial Officer2026-10-08D9,164——Derivative, Class A CommonForm 4 ↗
Joshua ReedSVP, Chief Financial Officer2026-10-08D4,06940163,208CommonForm 4 ↗
Joshua ReedSVP, Chief Financial Officer2026-10-08A9,164——CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Craig HopkinsonOPTION2025-02-19——63,991—$1,093,107
Blair JacksonRSU2025-02-19——37,203—1,333,356
Blair JacksonOPTION2025-02-19——77,565—1,324,981
C. Todd NicholsRSU2025-02-19——24,182—866,683
Joshua ReedOPTION2025-10-08——158,743—2,334,091
C. Todd NicholsOPTION2025-02-19——50,417—861,234
Joshua ReedRSU2025-10-08——36,656—1,155,031
David GaffinRSU2025-02-19——30,692—1,100,001
Craig HopkinsonRSU2025-02-19——30,692—1,100,001
Richard PopsOPTION2025-02-19——293,921—5,020,812
David GaffinOPTION2025-02-19——63,991—1,093,107
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Craig Hopkinson$1,100,001$0$1,093,1070.0%
Blair Jackson1,333,35601,324,9810.0%
C. Todd Nichols866,6830861,2340.0%
Joshua Reed1,155,03102,334,0910.0%
David Gaffin1,100,00101,093,1070.0%
Richard Pops005,020,8120.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Richard PopsPSU119,228—$3,335,999
David GaffinPSU23,019—644,072
Richard PopsRSU149,580—4,185,248
Blair JacksonRSU28,810—806,104
C. Todd NicholsRSU24,182—676,612
Richard PopsPSU127,205—3,559,196
Blair JacksonRSU24,967—698,577
C. Todd NicholsRSU21,127—591,133
Richard PopsRSU63,602—1,779,584
Craig HopkinsonRSU30,692—858,762
Blair JacksonRSU37,203—1,040,940
Joshua ReedRSU36,656—1,025,635
David GaffinRSU30,692—858,762
David GaffinPSU20,598—576,332
Blair JacksonPSU27,902—780,698
David GaffinRSU25,352—709,349
Blair JacksonRSU17,476—488,978
Richard PopsOption293,92135.84—
Craig HopkinsonRSU25,352—709,349
Blair JacksonOption77,56535.84—
Craig HopkinsonRSU20,598—576,332
Craig HopkinsonPSU20,598—576,332
Blair JacksonPSU24,967—698,577
C. Todd NicholsRSU6,355—177,813
Blair JacksonOption35,58624.59—
Craig HopkinsonOption63,99135.84—
Craig HopkinsonPSU23,019—644,072
Craig HopkinsonRSU8,897—248,938
Richard PopsOption145,28526.82—
C. Todd NicholsRSU12,815—358,564
David GaffinRSU20,598—576,332
Craig HopkinsonRSU10,299—288,166
Blair JacksonOption69,90226.82—
C. Todd NicholsOption25,41924.59—
C. Todd NicholsPSU18,136—507,445
C. Todd NicholsRSU16,229—454,087
Blair JacksonRSU12,483—349,274
C. Todd NicholsPSU16,288—455,738
Craig HopkinsonRSU15,379—430,304
Richard PopsOption76,25624.59—
C. Todd NicholsOption50,41735.84—
David GaffinRSU15,379—430,304
David GaffinRSU10,299—288,166
Richard PopsOption205,74630.04—
David GaffinOption61,51426.82—
Blair JacksonRSU8,897—248,938
C. Todd NicholsRSU8,114—227,030
David GaffinRSU6,355—177,813
David GaffinRSU2,015—56,380
Joshua ReedOption158,74331.51—
David GaffinOption7,34724.82—
Blair JacksonOption101,07930.04—
David GaffinOption25,41924.59—
David GaffinOption83,39030.04—
David GaffinOption63,99135.84—
Craig HopkinsonOption35,58624.59—
Craig HopkinsonOption61,51426.82—
Craig HopkinsonOption83,39030.04—
C. Todd NicholsOption51,26126.82—
C. Todd NicholsOption65,70230.04—
05

Incentive-plan design — the Compensation Discussion & Analysis

The executive compensation program is focused on attracting and retaining experienced and well-qualified executive officers who will help advance critical business objectives and rewarding them for performance that contributes meaningfully to the creation of shareholder value. The program structures a significant proportion of compensation as performance-based to align pay with performance and shareholder interests, while maintaining market competitiveness through peer comparisons.

CEO STI target (% of salary)150%
CEO LTI target (% of salary)—
Independent consultantAlpine Rewards LLC
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-20139,234,1761,787,311148,48898.73%Passed
20252025-05-21143,326,7431,891,000893,11598.7%Passed
20242024-05-31149,795,7022,358,534504,18898.45%Passed
20232023-06-29115,881,19930,815,867289,71278.99%Passed
20222022-07-07126,034,51019,942,73692,24686.34%Passed
20212021-06-1493,167,88635,087,053206,13272.64%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2098.73%a
20252025-05-2198.7%b
20242024-05-3198.45%c

a. Approved under the standard stated in the filing — “Abstentions and broker-non votes (if any) will have no effect on the outcome of this proposal, as they are not considered to be votes cast.”.

b. Approved under the standard stated in the filing — “Abstentions and broker-non votes (if any) will have no effect on the outcome of this proposal, as they are not considered to be votes cast.”.

c. Approved under the standard stated in the filing — “Abstentions and broker-non votes (if any) will have no effect on the outcome of this proposal, as they are not considered to be votes cast.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)30 : 1
CEO total compensation$7,936,648
Median employee compensation$266,757
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Frank Anders WilsonIndependent · Lead Independent Director · Audit and Risk · Nominating and Corporate Governance$152,220$187,515$187,499—$0$527,234
David A. Daglio JrIndependent · Not standing for re-election · Departed during FY39,401250,567226,46100516,429
Emily Peterson AlvaIndependent · Not standing for re-election · Departed during FY38,230250,567226,461—0515,258
Brian P. McKeonIndependent · Compensation · Nominating and Corporate Governance116,319187,515187,499—0491,333
Shane M. CookeIndependent · Audit and Risk (Chair) · Nominating and Corporate Governance109,737187,515187,499—0484,751
Nancy L. Snyderman, M.DIndependent · Audit and Risk · Financial Operating104,121187,515187,499—0479,135
Christopher I. Wright, M.D., Ph.DIndependent · Audit and Risk · Compensation102,829187,515187,499—0477,843
Nancy S. LurkerIndependent · Compensation · Nominating and Corporate Governance (Chair)101,198187,515187,499—0476,212
Richard B. Gaynor, M.DIndependent · Compensation (Chair)99,000187,515187,499—0474,014
Cato T. Laurencin, M.D., Ph.DIndependent · Financial Operating86,000187,515187,499—0461,014
Richard F. PopsEmployee director · Board Chair · Financial Operating000—00
09

Board fee structure and ownership guideline

Annual cash retainer$74,000
Annual equity retainer$375,000
Per board meeting fee$3,500
Committee chair fees (audit / comp / nom-gov)25,000 / 25,000 / 20,000
Stock ownership guideline$3
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$949,055
Equity awards (grant-date value)$2,001,254
All other compensation$0
Total cost of the board$2,950,309

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Alkermes plc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Alkermes plc..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2Incyte2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
3PTC Therapeutics2025Matthew Klein958,50016,593,8004,399,7601,294,00023,266,326
4Halozyme Therapeutics2025Helen Torley1,000,00019,350,1451,650,0141,147,50023,166,223
5BioMarin Pharmaceutical2025Alexander Hardy1,130,76916,833,6291,909,3101,644,50021,927,563
6Jazz Pharmaceuticals2025Renee Gala1,003,26916,138,43301,980,00019,151,558
7United Therapeutics2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
8Blueprint Medicines2024Kathryn Haviland821,3637,472,4804,315,144854,21713,477,004
9Neurocrine Biosciences2025Kyle Gano920,0005,750,0235,750,006013,448,935
10Ionis Pharmaceuticals2025Brett Monia1,051,7768,444,8381,438,105013,350,777
11Ultragenyx Pharmaceutical2025Emil Kakkis861,1008,364,9381,847,356299,66311,405,535
12Axsome Therapeutics2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
13Intra-Cellular Therapies2023Sharon Mates891,6537,749,9840010,086,413
14Acadia Pharmaceuticals2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
15Alkermes plc.2025Richard Pops1,250,76905,020,8121,626,0007,915,081
16Harmony Biosciences2025Jeffrey Dayno743,6001,976,5204,599,000558,0007,899,535
17Sarepta Therapeutics2025Douglas Ingram1,171,4256,000,0050649,0007,840,666

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Alkermes plc.130%PRSU 53 · RSU 24 · Option 23Yes — Relative Total Shareholder Return (TSR)Alpine Rewards LLC
Acadia Pharmaceuticals110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Axsome Therapeutics150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
BioMarin Pharmaceutical130%PSU 66 · RSU 21 · Options 13Yes — Relative TSRAon Human Capital Solutions
Blueprint Medicines130%RSU 37 · Options 32 · PSU 31Yes — Relative Total Stockholder Return (rTSR)Aon
Exelixis105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Halozyme Therapeutics127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
Harmony Biosciences100%not disclosednot disclosedPay Governance
Incyte138.6%Performance Shares 60 · RSU 40Yes — relative total shareholder return (TSR)Aon
Intra-Cellular Therapiesnot disclosedRSU 75 · PRSU 25Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology IndexAon Consulting, Inc.
Ionis Pharmaceuticalsnot disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Jazz Pharmaceuticals150%PSU 50 · RSU 50Yes — Relative TSRAon
Neurocrine Biosciences105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
PTC Therapeuticsnot disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.
Sarepta Therapeutics100%PSU 50 · Option 25 · RSU 25NoFW Cook
Ultragenyx Pharmaceutical44%PSU 60 · RSU 20 · Options 20Yes — Relative TSRAon's Human Capital Solutions Practice
United Therapeutics221%PSO 50 · PSU 50NoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Alkermes plc. in fiscal 2025?
As disclosed, Richard Pops (Chief Executive Officer and Chairman of the Board) was the highest-paid executive at Alkermes plc. in fiscal 2025, with total compensation of $7,915,081.
How does Alkermes plc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Richard Pops's total compensation ranked at the 12th percentile of Alkermes plc.'s disclosed peer group.
What is Alkermes plc.'s CEO-to-median employee pay ratio?
As disclosed, Alkermes plc.'s CEO-to-median employee pay ratio was 30:1.
How did shareholders vote on Alkermes plc.'s executive compensation?
As disclosed, 98.73% of shareholders supported Alkermes plc.'s executive compensation in the latest say-on-pay vote.
How much does Alkermes plc. spend in total on board compensation for fiscal 2025?
As disclosed, Alkermes plc. reported total board compensation of $2,950,309 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Richard PopsDEF 14A2026-04-060001193125-26-143977Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267
2Section 01, Blair JacksonDEF 14A2026-04-060001193125-26-143977Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 4,030,905. Filing ↗machine: r8 · c33 · span 2571116–2571125
3Section 01, Joshua ReedDEF 14A2026-04-060001193125-26-143977Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 3,797,074. Filing ↗machine: r6 · c33 · span 2548123–2548132
4Section 01, Craig HopkinsonDEF 14A2026-04-060001193125-26-143977Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 3,617,908. Filing ↗machine: r14 · c33 · span 2650583–2650592
5Section 01, David GaffinDEF 14A2026-04-060001193125-26-143977Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 3,470,083. Filing ↗machine: r11 · c33 · span 2610849–2610858
6Section 01, C. Todd NicholsDEF 14A2026-04-060001193125-26-143977Section “EXECUTIVE COMPENSATION TABLES” · page 106. As printed: 2,790,694. Filing ↗machine: r17 · c33 · span 2690295–2690304
7Section 03, Craig Hopkinson OPTIONDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r14 · c17 · span 2644790–2644799
8Section 03, Blair Jackson RSUDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r8 · c13 · span 2563873–2563882
9Section 03, Blair Jackson OPTIONDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r8 · c17 · span 2565323–2565332
10Section 03, C. Todd Nichols RSUDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r17 · c13 · span 2683056–2683063
11Section 03, Joshua Reed OPTIONDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r6 · c17 · span 2542331–2542340
12Section 03, C. Todd Nichols OPTIONDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r17 · c17 · span 2684504–2684511
13Section 03, Joshua Reed RSUDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r6 · c13 · span 2540881–2540890
14Section 03, David Gaffin RSUDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r11 · c13 · span 2603606–2603615
15Section 03, Craig Hopkinson RSUDEF 14A2026-04-060001193125-26-143977Section “ALKERMES PLC” · grants of plan-based awards table. Filing ↗machine: t119 · r14 · c13 · span 2643340–2643349
16Section 03, Richard Pops OPTIONDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r3 · c17 · span 2502463–2502472
17Section 03, David Gaffin OPTIONDEF 14A2026-04-060001193125-26-143977Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t119 · r11 · c17 · span 2605056–2605065
18Section 07, pay ratioDEF 14A2026-04-060001193125-26-143977Section “CEO Pay Ratio”. As printed: 30 : 1. Filing ↗machine: span 4726278–4726280
19Section 08, Frank Anders WilsonDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 527,234. Filing ↗machine: span 1078780–1079007
20Section 08, David A. Daglio JrDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 516,429. Filing ↗machine: span 1037400–1037627
21Section 08, Emily Peterson AlvaDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 515,258. Filing ↗machine: span 1023615–1023842
22Section 08, Brian P. McKeonDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 491,333. Filing ↗machine: span 1064985–1065212
23Section 08, Shane M. CookeDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 484,751. Filing ↗machine: span 1030505–1030732
24Section 08, Nancy L. Snyderman, M.DDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 479,135. Filing ↗machine: span 1071885–1072112
25Section 08, Christopher I. Wright, M.D., Ph.DDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 477,843. Filing ↗machine: span 1085690–1085917
26Section 08, Nancy S. LurkerDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 476,212. Filing ↗machine: span 1058094–1058321
27Section 08, Richard B. Gaynor, M.DDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 474,014. Filing ↗machine: span 1044298–1044525
28Section 08, Cato T. Laurencin, M.D., Ph.DDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 461,014. Filing ↗machine: span 1051203–1051430
29Section 08, Richard F. PopsDEF 14A2026-04-060001193125-26-143977Section “Director Compensation”. As printed: 0. Filing ↗
30Section 02, David Gaffin 2026-04-06Form 42026-04-060001520262-26-000067Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Nancy S. Lurker 2026-04-11Form 42026-04-130001520262-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Nancy S. Lurker 2026-04-11Form 42026-04-130001520262-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Nancy S. Lurker 2026-04-11Form 42026-04-130001520262-26-000070Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Craig Hopkinson 2026-05-01Form 42026-05-010001520262-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Craig Hopkinson 2026-05-01Form 42026-05-010001520262-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Craig Hopkinson 2026-05-01Form 42026-05-010001520262-26-000072Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, David Gaffin 2026-05-04Form 42026-05-040001520262-26-000074Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Richard Gaynor 2026-05-20Form 42026-05-220001520262-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, nancy lynn snyderman MD 2026-05-20Form 42026-05-220001520262-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Shane M. Cooke 2026-05-20Form 42026-05-220001520262-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Richard Gaynor 2026-05-20Form 42026-05-220001520262-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Richard Gaynor 2026-05-20Form 42026-05-220001520262-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Richard Gaynor 2026-05-20Form 42026-05-220001520262-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Shane M. Cooke 2026-05-20Form 42026-05-220001520262-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Shane M. Cooke 2026-05-20Form 42026-05-220001520262-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Shane M. Cooke 2026-05-20Form 42026-05-220001520262-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Cato T. Laurencin 2026-05-20Form 42026-05-220001520262-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Cato T. Laurencin 2026-05-20Form 42026-05-220001520262-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Nancy S. Lurker 2026-05-20Form 42026-05-220001520262-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Nancy S. Lurker 2026-05-20Form 42026-05-220001520262-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Brian P. McKeon 2026-05-20Form 42026-05-220001520262-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Brian P. McKeon 2026-05-20Form 42026-05-220001520262-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, nancy lynn snyderman MD 2026-05-20Form 42026-05-220001520262-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Frank Anders Wilson 2026-05-20Form 42026-05-220001520262-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Frank Anders Wilson 2026-05-20Form 42026-05-220001520262-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Christopher I. Wright 2026-05-20Form 42026-05-220001520262-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Christopher I. Wright 2026-05-20Form 42026-05-220001520262-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Cato T. Laurencin 2026-05-21Form 42026-05-220001520262-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Nancy S. Lurker 2026-05-21Form 42026-05-220001520262-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, nancy lynn snyderman MD 2026-05-21Form 42026-05-220001520262-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Frank Anders Wilson 2026-05-21Form 42026-05-220001520262-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Richard Gaynor 2026-05-21Form 42026-05-220001520262-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Richard Gaynor 2026-05-21Form 42026-05-220001520262-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Shane M. Cooke 2026-05-21Form 42026-05-220001520262-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Shane M. Cooke 2026-05-21Form 42026-05-220001520262-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Richard Gaynor 2026-05-21Form 42026-05-220001520262-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Cato T. Laurencin 2026-05-21Form 42026-05-220001520262-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Cato T. Laurencin 2026-05-21Form 42026-05-220001520262-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Nancy S. Lurker 2026-05-21Form 42026-05-220001520262-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Nancy S. Lurker 2026-05-21Form 42026-05-220001520262-26-000089Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Brian P. McKeon 2026-05-21Form 42026-05-220001520262-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Brian P. McKeon 2026-05-21Form 42026-05-220001520262-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Brian P. McKeon 2026-05-21Form 42026-05-220001520262-26-000090Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, nancy lynn snyderman MD 2026-05-21Form 42026-05-220001520262-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, nancy lynn snyderman MD 2026-05-21Form 42026-05-220001520262-26-000091Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Frank Anders Wilson 2026-05-21Form 42026-05-220001520262-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Christopher I. Wright 2026-05-21Form 42026-05-220001520262-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Christopher I. Wright 2026-05-21Form 42026-05-220001520262-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Christopher I. Wright 2026-05-21Form 42026-05-220001520262-26-000093Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Shane M. Cooke 2026-05-21Form 42026-05-220001520262-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Frank Anders Wilson 2026-05-21Form 42026-05-220001520262-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Samuel Joseph Parisi 2026-05-29Form 42026-05-290001520262-26-000095Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Samuel Joseph Parisi 2026-05-29Form 42026-05-290001520262-26-000095Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Samuel Joseph Parisi 2026-05-29Form 42026-05-290001520262-26-000095Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Samuel Joseph Parisi 2026-05-29Form 42026-05-290001520262-26-000095Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Samuel Joseph Parisi 2026-05-29Form 42026-05-290001520262-26-000095Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Craig Hopkinson 2026-06-01Form 42026-06-010001520262-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Craig Hopkinson 2026-06-01Form 42026-06-010001520262-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Craig Hopkinson 2026-06-01Form 42026-06-010001520262-26-000097Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, David Gaffin 2026-06-04Form 42026-06-040001520262-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Christopher I. Wright 2026-06-12Form 42026-06-120001520262-26-000101Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Craig Hopkinson 2026-07-01Form 42026-07-010001520262-26-000103Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Craig Hopkinson 2026-07-01Form 42026-07-010001520262-26-000103Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Craig Hopkinson 2026-07-01Form 42026-07-010001520262-26-000103Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Craig Hopkinson 2026-07-01Form 42026-07-010001520262-26-000103Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, David Gaffin 2026-07-06Form 42026-07-060001520262-26-000105Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, nancy lynn snyderman MD 2026-08-03Form 42026-08-030001520262-26-000111Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, nancy lynn snyderman MD 2026-08-03Form 42026-08-030001520262-26-000111Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Craig Hopkinson 2026-08-03Form 42026-08-030001520262-26-000110Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, David Gaffin 2026-08-03Form 42026-08-030001520262-26-000109Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Craig Hopkinson 2026-08-03Form 42026-08-030001520262-26-000110Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Craig Hopkinson 2026-08-03Form 42026-08-030001520262-26-000110Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Craig Hopkinson 2026-08-03Form 42026-08-030001520262-26-000110Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, nancy lynn snyderman MD 2026-08-03Form 42026-08-030001520262-26-000111Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Craig Hopkinson 2026-08-03Form 42026-08-030001520262-26-000110Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, nancy lynn snyderman MD 2026-08-03Form 42026-08-030001520262-26-000111Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, nancy lynn snyderman MD 2026-08-03Form 42026-08-030001520262-26-000111Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Blair Jackson 2026-08-05Form 42026-08-070001520262-26-000113Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Blair Jackson 2026-08-05Form 42026-08-070001520262-26-000113Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, C. Todd Nichols 2026-08-17Form 42026-08-170001520262-26-000116Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, C. Todd Nichols 2026-08-17Form 42026-08-170001520262-26-000116Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Craig Hopkinson 2026-09-01Form 42026-09-010001520262-26-000118Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Craig Hopkinson 2026-09-01Form 42026-09-010001520262-26-000118Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Craig Hopkinson 2026-09-01Form 42026-09-010001520262-26-000118Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, David Gaffin 2026-09-03Form 42026-09-030001520262-26-000120Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, David Gaffin 2026-10-02Form 42026-10-020001520262-26-000127Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Anne Clem Whitaker 2026-10-07Form 42026-10-090001520262-26-000130Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Anne Clem Whitaker 2026-10-07Form 42026-10-090001520262-26-000130Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Joshua Reed 2026-10-08Form 42026-10-090001520262-26-000131Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Joshua Reed 2026-10-08Form 42026-10-090001520262-26-000131Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Joshua Reed 2026-10-08Form 42026-10-090001520262-26-000131Insider equity transaction reported since the proxy statement. Filing ↗
122Section 06, 2026 voteForm 8-K2026-05-200001193125-26-232584Item 5.07 · say-on-pay result. As reported: 98.73% (votes for as printed: 139,234,176). Filing ↗
123Section 06, 2025 voteForm 8-K2025-05-210000950170-25-075783Item 5.07 · say-on-pay result. As reported: 98.7% (votes for as printed: 143,326,743). Filing ↗
124Section 06, 2024 voteForm 8-K2024-05-310000950170-24-067296Item 5.07 · say-on-pay result. As reported: 98.45% (votes for as printed: 149,795,702). Filing ↗
125Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
126Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
127Section 09b board cost (computed)Computed——Cash 949,055 + equity 2,001,254 + all other 0 = 2,950,309, summed across the director compensation table rows.machine: formula: Σ = 2,950,309
128Exelixis, Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis's own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
129Incyte, Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in Incyte's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
130PTC Therapeutics, Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. Filing ↗
131Halozyme Therapeutics, Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
132BioMarin Pharmaceutical, Section 10b CEO totalDEF 14A2026-04-210001628280-26-026290CEO total compensation as printed in BioMarin Pharmaceutical's own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915
133Jazz Pharmaceuticals, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
134United Therapeutics, Section 10b CEO totalDEF 14A2026-04-290001082554-26-000009CEO total compensation as printed in United Therapeutics's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736
135Blueprint Medicines, Section 10b CEO totalDEF 14A2025-04-240001558370-25-005415CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162
136Neurocrine Biosciences, Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
137Ionis Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. Filing ↗
138Ultragenyx Pharmaceutical, Section 10b CEO totalDEF 14A2026-03-270001308179-26-000174CEO total compensation as printed in Ultragenyx Pharmaceutical's own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007
139Axsome Therapeutics, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
140Intra-Cellular Therapies, Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular Therapies's own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
141Acadia Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in Acadia Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗
142Alkermes plc. (subject), Section 10b CEO totalDEF 14A2026-04-060001193125-26-143977CEO total compensation as printed in Alkermes plc.'s own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267
143Harmony Biosciences, Section 10b CEO totalDEF 14A2026-04-030001104659-26-039449CEO total compensation as printed in Harmony Biosciences's own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364
144Sarepta Therapeutics, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177247CEO total compensation as printed in Sarepta Therapeutics's own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404
145Section 10a, Acadia Pharmaceuticals reciprocityDEF 14A—0001193125-26-174163Acadia Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Alkermes plc.. Filing ↗
146Section 10a, Axsome Therapeutics reciprocityDEF 14A—0001193125-26-177610Axsome Therapeutics's most recent proxy was read; its disclosed peer group does not include Alkermes plc.. Filing ↗
147Section 10a, BioMarin Pharmaceutical reciprocityDEF 14A—0001628280-26-026290BioMarin Pharmaceutical's most recent proxy was read; its disclosed peer group does not include Alkermes plc.. Filing ↗
148Section 10a, Blueprint Medicines reciprocityDEF 14A—0001558370-25-005415Blueprint Medicines names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
149Section 10a, Exelixis reciprocityDEF 14A—0000939767-26-000046Exelixis names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
150Section 10a, Halozyme Therapeutics reciprocityDEF 14A—0001159036-26-000041Halozyme Therapeutics names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
151Section 10a, Harmony Biosciences reciprocityDEF 14A—0001104659-26-039449Harmony Biosciences names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
152Section 10a, Ionis Pharmaceuticals reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
153Section 10a, Jazz Pharmaceuticals reciprocityDEF 14A—0001232524-26-000029Jazz Pharmaceuticals names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
154Section 10a, PTC Therapeutics reciprocityDEF 14A—0001104659-26-045528PTC Therapeutics names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
155Section 10a, Sarepta Therapeutics reciprocityDEF 14A—0001193125-26-177247Sarepta Therapeutics names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
156Section 10a, Ultragenyx Pharmaceutical reciprocityDEF 14A—0001308179-26-000174Ultragenyx Pharmaceutical names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
157Section 10a, United Therapeutics reciprocityDEF 14A—0001082554-26-000009United Therapeutics names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗
158Section 10a, Intra-Cellular Therapies reciprocityDEF 14A—0001628280-24-018986Intra-Cellular Therapies's most recent proxy was read; its disclosed peer group does not include Alkermes plc.. Filing ↗
159Section 10a, Neurocrine Biosciences reciprocityDEF 14A—0000914475-26-000015Neurocrine Biosciences names Alkermes plc. in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Alkermes plc. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
ALKS Peer Teardown Report